PofoliaShared via Pofolia

Scientific Reports· 2026Q1

Dexmedetomidine enhances ultrasound-guided sciatic nerve block in rats by reducing perineural capillary permeability via RhoA/ROCK-MLC signaling

Yiling Lin, Youmei Wu, Qianqian Ye, Yun Xia et al.

Short summary

Dexmedetomidine (DEX) prolongs sciatic nerve block analgesia in rats by reducing perineural capillary permeability, delaying ropivacaine's systemic absorption.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Dexmedetomidine (DEX) prolonged ropivacaine sciatic nerve block analgesia in rats, with a half-life of 5.34h.
  • DEX reduced perineural capillary permeability, as indicated by decreased Evans blue dye extravasation.
  • DEX strengthened endothelial barrier integrity, confirmed by Transwell assays.
  • The RhoA/ROCK-MLC signaling pathway was downregulated by DEX, identified through RNA-seq and Western blotting.

AI-generated from the title and abstract; the full text is not read.

Abstract

Dexmedetomidine (DEX) is widely used as an adjuvant to local anesthetics to prolong the duration of nerve block-induced analgesia. Despite its clinical efficacy, the precise mechanisms by which DEX enhances and extends analgesic effects remain incompletely understood. An ultrasound-guided rat sciatic nerve block model was established. Twenty four male Sprague-Dawley rats were divided in four groups ( n = 6): ropivacaine + dexmedetomidine (ROP + DEX) group; ropivacaine + normal saline (ROP + NS) group; dexmedetomidine + normal saline (DEX + NS) group, and normal saline (NS) group. Analgesic effects were assessed via mechanical and thermal sensitivity testing. Ropivacaine plasma concentrations were determined using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Capillary permeability was assessed by two-photon intravital imaging using Evans blue dye (EBD) extravasation and Transwell assays. RNA sequencing and Western blotting were performed to identify underlying molecular pathways. The ROP+DEX group demonstrated significantly prolonged analgesia when compared to the ROP+NS group, with an extended t₁/₂ (5.34 h), increased AUC, and a reduced clearance rate (CL), indicating slower systemic absorption of ropivacaine. Two-photon imaging and EBD assays demonstrated reduced perineural capillary leakage. Transwell experiments confirmed that DEX strengthens endothelial barrier integrity. RNA-seq and Gene Ontology (GO) analysis highlighted enrichment in cytoskeletal and adhesion-related pathways, and Western blotting revealed decreased activation of the RhoA/ROCK-MLC signaling pathway in the ROP+DEX group. Dexmedetomidine enhances local anesthetic efficacy by reducing perineural capillary permeability and delaying systemic absorption. This effect is likely mediated through the RhoA/ROCK-MLC signaling pathway, offering a mechanistic basis for its use as an adjuvant in regional anesthesia.

The authors' abstract, as published at the source. Scientific Reports, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Neurology (Neuroscience)

NeurologyNeuroscience